Cathie Wood Doubles Down on Ionis Pharmaceuticals Amid Eplontersen Setback and Tryngolza Market Expansion
核心洞察
Cathie Wood's ARK Genomic Revolution ETF (搜索) has purchased $15.3 million in Ionis Pharmaceuticals (搜索) shares since July, following a late-stage trial failure for eplontersen in ATTR-CM that sent the stock down nearly 37% from its 2026 high.
The FDA approved Tryngolza (olezarsen) in June 2026 for severe hypertriglyceridemia (搜索), expanding the addressable U.S. market from approximately 3,000 FCS patients to over 3 million sHTG patients.
In clinical trials, Tryngolza reduced triglycerides by up to 72% and cut acute pancreatitis events by 85% to 91%, making it the only approved sHTG therapy shown to dramatically reduce pancreatic risk.
Cathie Wood's ARK Genomic Revolution ETF (搜索) has acquired $15.3 million worth of Ionis Pharmaceuticals (搜索) shares since the beginning of July, capitalizing on a sharp stock decline triggered by a surprise late-stage trial failure. The purchases came after Ionis and its partner AstraZeneca announced that eplontersen, an investigational therapy for transthyretin amyloidosis cardiomyopathy (搜索) (ATTR-CM), failed to meet its endpoints in a pivotal trial. The stock has fallen nearly 37% from its 2026 high, and all of Wood's recent buying occurred after the announcement, signaling a long-term conviction in the Carlsbad, California-based biotech.
The setback means Ionis will not share in profits, sales royalties, or future milestone payments for eplontersen in the ATTR-CM indication. However, eplontersen was previously approved in 2023 for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, providing an ongoing revenue stream from that indication.
Tryngolza Label Expansion Transforms the Commercial Picture
Just weeks before the eplontersen disappointment, Ionis secured a transformative regulatory win. In June 2026, the U.S. Food and Drug Administration approved Tryngolza (olezarsen) for the treatment of severe hypertriglyceridemia (搜索) (sHTG), a condition marked by dangerously elevated blood triglyceride levels. This follows Tryngolza's initial 2024 approval for familial chylomicronemia syndrome (搜索) (FCS), an ultra-rare disorder affecting only about 3,000 people in the United States.
The sHTG approval dramatically expands the drug's addressable market to more than 3 million potential patients in the U.S. alone. In clinical trials, Tryngolza demonstrated a reduction in triglyceride levels of up to 72% and, critically, reduced life-threatening acute pancreatitis events by 85% to 91%. It remains the only approved therapy for sHTG that has been shown to dramatically reduce this specific pancreatic risk, conferring a significant competitive advantage.
Strategic Pivot to Wholly Owned Commercialization
Ionis is undergoing a fundamental strategic shift, moving from its historical model as a research and development engine that licensed assets to larger pharmaceutical partners — including Biogen and AstraZeneca — toward controlling the commercialization of its own therapies. The company is leading the commercial launch of Tryngolza, capturing high-margin revenue directly.
In a notable pricing strategy, Ionis proactively reduced Tryngolza's annual list price from $595,000, its ultra-orphan drug price point, to $40,000 per year to facilitate rapid insurer coverage and broad patient access. Wall Street analysts, including William Blair, project that the substantial sHTG patient volume could drive Tryngolza's peak sales to $3 billion. This trajectory supports Ionis's guidance to reach the cash flow break-even point by 2028.
The financial impact is already materializing. Ionis reported $246 million in revenue for the first quarter, an 86% increase year over year, while narrowing its net loss from $146 million to $118 million over the same period. The company also raised its annual Tryngolza peak net sales guidance from $2 million to $3 million.
One area of caution involves the cost of commercialization. Ionis reported that its cash, cash equivalents, and short-term investments declined from $2.7 billion to $1.9 billion in the first quarter. While much of this decrease stemmed from paying off maturing convertible debt, operating expenses are scaling rapidly to fund launch preparations for Tryngolza, zilganersen, and other wholly owned pipeline assets.
Late-Stage Pipeline Offers Multiple Catalysts
Beyond Tryngolza, Ionis maintains a diverse, clinically validated RNA-targeted pipeline with significant readouts and regulatory catalysts anticipated through the remainder of 2026 and into 2027. In March, the FDA accepted the company's New Drug Application with Priority Review for zilganersen, an investigational therapy for Alexander disease (搜索), a rare neurological disorder.
A high-profile phase 3 readout is also expected shortly for pelacarsen, partnered with Novartis. The therapy is being evaluated for its ability to reduce the risk of heart attack or stroke in patients with established cardiovascular disease and elevated levels of Lipoprotein(a), a genetically determined form of cholesterol.
Because Ionis's antisense oligonucleotide platform is already clinically proven, the company's pipeline carries a higher probability of success compared with early-stage, speculative biotechnology firms. However, as Ionis transitions to a commercial-stage enterprise, it faces uncharted territory — any late-stage readout failure or revenue shortfall could pressure the stock, and rising marketing costs may divert resources from research and development efforts.